Literature DB >> 933467

Urinary kallikrein in experimental renal disease.

R J Glasser, A F Michael.   

Abstract

Urinary kallikrein excretion was studied in two types of experimentally induced renal disease: anti-glomerular basement membrane nephritis (20 rats) and aminonucleoside nephrosis (five rats) with appropriate controls (23 rats) for a period of 6 to 9 weeks following disease induction. In both models there was a prompt significant decrease (p less than 0.01 - 0.001) in urinary kallikrein excretion associated with proteinuria but unrelated to urinary sodium and potassium excretion and urinary volumes. In antiglomerular basement membrane nephritis the fall in kallikrein excretion occurred within the first 24 hours concurrent with the onset of proteinuria. In aminonucleoside nephrosis the decrease antedated the onset of proteinuria by 48 hours beginning within the first 24 hours following injection of the aminonucleoside. Kallikrein inhibitors were not demonstrable in the urines of diseased animals from either model. The mechanism of the decrease in kallikrein excretion in immune and nonimmune glomerular disease associated with proteinuria is unknown.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 933467

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  5 in total

1.  Plasma renin activity and urinary kallikrein excretion in response to intravenous furosemide in diabetic patients.

Authors:  S B Lall; S Kunchaparty; H H Siddiqui; J S Bajaj
Journal:  Acta Diabetol Lat       Date:  1990 Oct-Dec

2.  Renal kallikrein in diabetic patients with hypertension accompanied by nephropathy.

Authors:  T Baba; S Murabayashi; T Ishizaki; Y Ido; K Aoyagi; K Takebe
Journal:  Diabetologia       Date:  1986-03       Impact factor: 10.122

Review 3.  The renal kallikrein-kinin system in human and in experimental hypertension.

Authors:  O A Carretero; A G Scicli
Journal:  Klin Wochenschr       Date:  1978

4.  Altered renal kallikrein and renin gene expression in nephrotic rats and modulation by converting enzyme inhibition.

Authors:  F N Hutchison; S K Webster; A A Jaffa
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

5.  Urinary kallikrein excretion in essential and mineralocorticoid hypertension.

Authors:  O B Holland; J M Chud; H Braunstein
Journal:  J Clin Invest       Date:  1980-02       Impact factor: 14.808

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.